CD8A and neoplasm: In addition, combined with anti‐CTLA‐4 immunotherapy, personalized tumor‐specific CD8+ T cells responses might be triggered in patients who do not respond to immune checkpoint blockade alone.[116] Taking advantage of the solid properties of PLGA NPs, Chen et al.